.png)
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Ultivue provides researchers with the clearest profile of cancer biology, enabling them to see more, see faster, and see in situ. Through clinical-grade InSituPlex® assays and advanced AI-driven STARVUE™ spatial image analysis pipeline, Ultivue empowers scientists developing precision cancer therapies to gain quantitative, high-confidence insights in just a fraction of the time.
With over 15 years of experience in genetic and epigenetic clinical research, EpigenDx offers high quality products and laboratory services focused on DNA methylation analysis, gene expression profiling, and mutation analysis. Our scientific teams carefully evaluate each project and establish analysis procedures using best fit technologies, including NGS, Pyrosequencing, RT-PCR, digital PCR, and GeneChip Microarray. Our popular services include Line-1 global methylation tests and Foxp3-TSDR analysis for epigenetic immunotherapy. Our GLP compliant and CLIA certified services make us the perfect partner during pre-clinical research and diagnostic test development.
-.png)
Ground Truth Labs (GTL) has developed AI-powered computer vision algorithms to quantify complex spatial biomarkers from digital images of standard histopathology slides. Analysis is non-tissue destructive and results can be provided in near real-time, powering patient stratification in clinical trials and effectively measuring response to intervention.
Randox Biosciences is dedicated to advancing scientific discovery, drug development and diagnostics. Our aim is to advance the future of personalized approaches and assist Pharma Biotechs and CROs move away from the “one treatment fits all” approach. Our pharma Services division hosts unrivalled expertise in diagnostic and CDx assay development.
With more than 150 sites in 21 countries, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving your product’s unique challenges. Our focus on timeliness and accuracy in every stage of development means you can count on reliable, reproducible results – throughout your journey.
Agilent provides laboratories with solutions enabling customers to gain the insights they seek. Agilent focuses on key markets. Food: Agilent helps ensure that our global food supply is free of contaminants. Diagnostics: Agilent gives doctors a head start in the fight against cancer and genetic diseases. Research: Agilent helps these researchers learn more about diverse ailments. Pharmaceutical: Agilent provides precise answers for the pharmaceutical industry, from drug discovery to drug development, manufacturing and quality control.
Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins. The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments. RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX.
ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical devices and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 106 locations in 53 countries as of September 30, 2023. For further information about ICON, visit: www.iconplc.com
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. Akoya offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers the PhenoCycler™ and PhenoImager™ platforms to serve the diverse needs of researchers across discovery, translational and clinical research.
